William Blair Brokers Lift Earnings Estimates for Genmab A/S

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Friday, October 10th. William Blair analyst M. Phipps now expects that the company will earn $0.47 per share for the quarter, up from their previous estimate of $0.46. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S’s FY2025 earnings at $1.75 EPS.

Other research analysts have also issued reports about the company. Wall Street Zen upgraded Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. Zacks Research upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Tuesday, September 23rd. Finally, HC Wainwright upped their target price on Genmab A/S from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $40.80.

Genmab A/S Trading Down 0.1%

Shares of NASDAQ GMAB opened at $31.81 on Monday. The business has a fifty day simple moving average of $26.86 and a 200 day simple moving average of $22.91. The firm has a market capitalization of $20.42 billion, a price-to-earnings ratio of 15.98, a PEG ratio of 1.79 and a beta of 0.98. Genmab A/S has a one year low of $17.24 and a one year high of $33.63.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC boosted its holdings in Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after acquiring an additional 1,464 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC boosted its holdings in Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after acquiring an additional 1,070 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after acquiring an additional 1,174 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.